Treatment Utilization and Characteristics Among Patients with Higher-Risk Myelodysplastic Syndromes According to Hypomethylating Agent Use

被引：0
|
作者：
Zeidan, Amer M. [1 ,2 ]
Divino, Victoria [3 ]
DeKoven, Mitch [3 ]
Shah, Drishti [3 ]
Wang, Elizabeth [3 ]
Bey, Dawn [4 ]
Salimi, Tehseen [5 ]
Epstein, Robert S. [6 ]
机构：
[1] Yale Univ, New Haven, CT USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] IQVIA, Real World Insights, Falls Church, VA USA
[4] Taiho Oncol Inc, Evidence & Value Dev Field Med Affairs, Princeton, NJ USA
[5] Taiho Oncol Inc, Med Affairs & Real World Evidence, Princeton, NJ USA
[6] Epstein Hlth, Woodcliff Lake, NJ USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-144852
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5030
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Predictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes.
    Zeidan, Amer Methqal
    Joshi, Namita
    Kale, Hrishikesh
    Wang, Wei-Jhih
    Corman, Shelby
    Hill, Kala
    Salimi, Tehseen
    Epstein, Robert S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] HOSPITALIZATION AND EMERGENCY ROOM VISITS AMONG PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES BY HYPOMETHYLATING AGENT USE
    Zeidan, A. M.
    Joshi, N.
    Kale, H.
    Wang, W. -J.
    Corman, S.
    Hill, K.
    Salimi, T.
    Epstein, R.
    [J]. LEUKEMIA RESEARCH, 2021, 108 : S26 - S26
  • [3] Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents
    Komrokji, Rami S.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S56 - S59
  • [4] Decitabine treatment of patients with higher-risk myelodysplastic syndromes
    Steensma, David P.
    [J]. LEUKEMIA RESEARCH, 2009, 33 : S12 - S17
  • [5] Impact of Hypomethylating Agent Use on Hospital and Emergency Room Visits, and Predictors of Early Discontinuation in Patients With Higher-Risk Myelodysplastic Syndromes
    Zeidan, Amer M.
    Joshi, Namita
    Kale, Hrishikesh
    Wang, Wei-Jhih
    Corman, Shelby
    Salimi, Tehseen
    Epstein, Robert S.
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (09): : 670 - 679
  • [6] Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
    Bewersdorf, Jan Philipp
    Zeidan, Amer M.
    [J]. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2021, 34 (01)
  • [7] Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
    Lee, Sangmin
    Mohan, Sanjay
    Knupp, Jessica
    Chamoun, Kamal
    de Jonge, Adrienne
    Yang, Fan
    Baloglu, Erkan
    Shah, Jatin
    Kauffman, Michael G.
    Shacham, Sharon
    Bhatnagar, Bhavana
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [8] Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
    Sangmin Lee
    Sanjay Mohan
    Jessica Knupp
    Kamal Chamoun
    Adrienne de Jonge
    Fan Yang
    Erkan Baloglu
    Jatin Shah
    Michael G. Kauffman
    Sharon Shacham
    Bhavana Bhatnagar
    [J]. Journal of Hematology & Oncology, 15
  • [9] The Direct Medical Costs of Treatment Discontinuation Among Higher-Risk Myelodysplastic Syndrome Patients Receiving Hypomethylating Agents
    Joshi, Namita
    Kale, Hrishikesh P.
    Corman, Shelby
    Hill, Kala
    Wert, Tim
    Zeidan, Amer M.
    [J]. BLOOD, 2020, 136
  • [10] Efficacy and safety analysis of venetoclax combined with hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes in the real world
    高清妍
    [J]. China Medical Abstracts(Internal Medicine)., 2024, 41 (03)
12345